Research programme: oral biotherapeutics - Rani Therapeutics

Drug Profile

Research programme: oral biotherapeutics - Rani Therapeutics

Alternative Names: Adalimumab oral - Rani Therapeutics; Etanercept oral - Rani Therapeutics; Insulin oral - Rani Therapeutics; RaniPill™

Latest Information Update: 26 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rani Therapeutics
  • Class Anti-TNF monoclonal antibodies; Insulins; Peptides; Proteins; Recombinant fusion proteins; Vaccines
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Inflammation

Most Recent Events

  • 08 Feb 2018 Rani Therapeutics plans a clinical trial for Undefined indication in USA in 2019
  • 11 Oct 2016 Rani Therapeutics has 30 patents issued and more than 80 patents filed
  • 06 Jan 2016 Rani Therapeutics and MedImmune agree to conduct feasibility studies for oral delivery of injectable drugs for Metabolic disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top